medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2021, Número 3

<< Anterior

Cir Card Mex 2021; 6 (3)


Declaración de Sociedad Mexicana de Cirugía Cardiaca, A. C. y el Colegio Mexicano de Cirugía Cardiovascular y Torácica, A. C. respecto a las nuevas guías clínicas 2020 para el manejo del paciente con enfermedad valvular cardiaca de la American College of Cardiology/American Heart Association

García-Villarreal OA, Heredia-Delgado JA, Lezama-Urtecho CA, Espinoza-Hernández JD, Roldán-Morales D, Juárez-Hernández A, Oviedo-Pérez R, Rodríguez-Durán LE, Hernández-Mejía BI, Orozco-Hernández EJ, Siordia-Zamorano RE, Calderón-Abbo MC, Parra-Salazar JJ, Barragán-García R

Idioma: Español
Referencias bibliográficas: 28
Paginas: 79-83
Archivo PDF: 207.45 Kb.


FRAGMENTO

La American College of Cardiology, American Heart Association y demás Sociedades involucradas han emitido las nuevas guías clínicas 2020 para el manejo del paciente con enfermedad valvular cardiaca [1]. Estas Sociedades deben de ser reconocidas por este monumental y minucioso trabajo. Estas guías clínicas representan un gran avance en los flujogramas y recomendaciones para la toma de decisiones concernientes al paciente con enfermedad valvular cardiaca.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for theManagement of Patients With Valvular Heart Disease: Executive Summary: AReport of the American College of Cardiology/American Heart Association JointCommittee on Clinical Practice Guidelines. Circulation 2021;143(5):e35-e71. doi:10.1161/CIR.0000000000000932.

  2. O’Brien SM, Shahian DM, Filardo G, et al. The Society of Thoracic Surgeons2008 cardiac surgery Risk models: part 2- isolated valve surgery. Ann Thorac Surg2009;88(1 suppl):S 23-42.

  3. Nashef S, Roques F, Sharples L, et al. EuroSCORE II Eur J Cardiothorac Surg2012;41:1-12. 7.

  4. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic - valvereplacement in high - risk patients. N Engl J Med 2011;364:2187-98. 1.

  5. Leon MB, Smith CR, Mack MJ, et al. Transcatheter aortic- valve implantationfor Aortic stenosis in patients who cannot undergo surgery. N Engl J Med2010;363:1597-607.

  6. Reardon MJ, Van Mieghem NM, Popma JJ, et al; SURTAVI Investigators. Surgicalor Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. NEngl J Med. 2017;376(14):1321-1331. doi: 10.1056/NEJMoa1700456.

  7. Popma JJ, Deeb GM, Yakubov SJ, et al., on behalf of the Evolut Low Risk TrialInvestigators. Transcatheter Aortic-Valve Replacement With a Self-ExpandingValve in Low-Risk Patients. N Engl J Med 2019;380:1706-15.

  8. Mack MJ, Leon MB, Thourani VH, et al; PARTNER 3 Investigators. TranscatheterAortic-Valve Replacement with a Balloon-Expandable Valve in Low-RiskPatients. N Engl J Med. 2019;380(18):1695-1705. doi: 10.1056/NEJMoa1814052.

  9. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of TranscatheterAortic Valve Replacement. J Am Coll Cardiol. 2020;76(21):2492-2516. doi:

  10. 10.1016/j.jacc.2020.09.595.10. Mahaffey JH, Haywood NS, Hawkins RB, et al. Need for permanent pacemakerafter surgical aortic valve replacement reduces long-term survival. Ann ThoracSurg 2018; 106:460-5.

  11. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosisin surgical and transcatheter bioprosthetic aortic valves: an observational study.Lancet 2017; 389:2383-92.

  12. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical Bioprosthetic Heart ValveThrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics,and Treatment Outcomes. JACC Cardiovasc Interv 2017; 10:686-97.

  13. Sun JC, Davidson MJ, Lamy A, et al. Antithrombotic management of patientswith prosthetic heart valves: current evidence and future trends. Lancet 2009;374:565–76.

  14. Pache G, Blanke P, Zeh W, et al. Cusp thrombosis after transcatheter aortic valvereplacement detected by computed tomography and echocardiography. Eur HeartJ 2013; 34:3546.

  15. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosisin bio- prosthetic aortic valves. N Engl J Med 2015;373: 2015–24.

  16. Alavi SH, Groves EM, Kheradvar A. The effects of transcatheter valve crimpingon pericardial leaflets. Ann Thorac Surg 2014; 97:1260–6.

  17. Thubrikar MJ, Deck JD, Aouad J, Nolan SP. Role of mechanical stress in calcificationof aortic bio- prosthetic valves. J Thorac Cardiovasc Surg 1983; 86:115–25.

  18. Leon MB, Mack MJ, Hahn RT, et al; PARTNER 3 Investigators. Outcomes 2Years After Transcatheter Aortic Valve Replacement in Patients at Low SurgicalRisk. J Am Coll Cardiol. 2021;77:1149-61. doi: 10.1016/j.jacc.2020.12.052.

  19. Barili F, Freemantle N, Pilozzi Casado A, et al. Mortality in trials on transcatheteraortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of Kaplan-Meier-derived individual patient data. Eur J CardiothoracSurg. 2020;58:221-9. doi: 10.1093/ejcts/ezaa087.

  20. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al; COAPTInvestigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. NEngl J Med. 2018; 379:2307-18.

  21. Obadia J-F, Messika-Zeitoun D, Leurent G, et al, for the MITRA-FR Investigators.Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation.N Engl J Med 2018; 379:2297-306. doi: 10.1056/NEJMoa1805374.

  22. Messika-Zeitoun D, Iung B, et al. Impact of Mitral Regurgitation Severity and LeftVentricular Remodeling on Outcome After Mitraclip Implantation: Results Fromthe Mitra-FR Trial. JACC Cardiovasc Imaging. 2020:S1936-878X(20)30645-8.doi: 10.1016/j.jcmg.2020.07.021.

  23. Alfieri O, Maisano F, De Bonis M, et al. The double-orifice technique in mitralvalve repair: a simple solution for complex problems. J Thorac Cardiovasc Surg2001;122:674-81. doi: 10.1067/mtc.2001.117277.

  24. De Bonis M, Lapenna E, Taramasso M, et al. Very long-term durability of theedge-to-edge repair for isolated anterior mitral leaflet prolapse: up to 21 years ofclinical and echocardiographic results. J Thorac Cardiovasc Surg 2014;148:2027-32. doi: 10.1016/j.jtcvs.2014.03.041.

  25. De Bonis M, Lapenna E, Maisano F, Barili F, La Canna G, Buzzatti N, PappalardoF, Calabrese M, Nisi T, Alfieri O. Long-term results (≤18 years) of the edge-toedgemitral valve repair without annuloplasty in degenerative mitral regurgitation:implications for the percutaneous approach. Circulation 2014;130(11 Suppl1):S19-24. doi: 10.1161/CIRCULATIONAHA.113.007885.

  26. De Bonis M, Lapenna E, Pozzoli A, Giacomini A, Alfieri O. Edge-to-edge surgicalmitral valve repair in the era of MitraClip: what if the annuloplasty ring is missed?Curr Opin Cardiol 2015;30(2):155-60. doi: 10.1097/HCO.0000000000000148.

  27. Del Forno B, Castiglioni A, Sala A, Geretto A, Giacomini A, Denti P, De Bonis M,Alfieri O. Mitral valve annuloplasty. Multimed Man Cardiothorac Surg. 2017.doi:10.1510/mmcts.2017.016.

  28. Feldman T, Kar S, Elmariah S, et al. EVEREST II Investigators. RandomizedComparison of Percutaneous Repair and Surgery for Mitral Regurgitation: 5-YearResults of EVEREST II. J Am Coll Cardiol 2015;66:2844-54. doi: 10.1016/j.jacc.2015.10.018.




2020     |     www.medigraphic.com